Loading stock data…
Mesoblast Limited (MESO)
$13.61+0.42 (+3.18%)
After Hours$13.61+0.00 (+0.00%)· Last close Jun 29
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Mesoblast Limited in the Healthcare sector is trading at $13.61 with a market capitalization of $1.8B. Wall Street consensus targets $35.00 (2 analysts), implying a +157.2% move over the next 12 months. The stock is currently 37% below its 52-week high of $21.50, remaining 16.2% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +157.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | — | — | — |
| Net Income | — | — | — | — | — |
Peer Comparison
JNJUNHPFE
Fundamentals
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.77B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-14.25%
Volume
Today's trading volume
150,570
Recent News
Kina Securities And 2 Other Stocks That May Be Trading Below Their Estimated Value On The ASX
In the midst of a challenging period for Australian shares, with market sentiment swayed by geopolitical tensions and economic uncertainties, investors are increasingly on the lookout for opportunities in undervalued stocks. Identifying stocks that may be trading below their estimated value can offer potential upside, especially when broader market volatility prompts a shift towards more defensive investment strategies.
ASX Growth Companies With High Insider Ownership
As Australian shares rebound from a significant market downturn, driven by global events and domestic fiscal policies, investors are keenly observing the landscape for opportunities. In this environment, growth companies with high insider ownership can be particularly appealing due to their potential for alignment of interests between management and shareholders.
ASX Penny Stocks With Market Caps Under A$3B To Consider
Australian shares are poised for a slight retreat, influenced by Wall Street's recent cooling and ongoing global economic discussions. Despite the fluctuating market conditions, penny stocks—often overlooked due to their smaller size or newer status—can still present valuable opportunities when backed by solid financials. In this article, we explore several promising Australian penny stocks that combine financial strength with potential for long-term growth.
ASX Stocks Trading At An Estimated Discount Of Up To 45.8% Below Intrinsic Value
The Australian share market is experiencing a downturn, influenced by the recent budget announcement and external pressures such as rising U.S. inflation, which has caused some uncertainty among investors. In this environment, identifying undervalued stocks can be an effective strategy for investors looking to capitalize on potential discounts relative to intrinsic value.
How Completion Of RMAT Phase 3 Enrollment At Mesoblast (ASX:MSB) Has Changed Its Investment Story
Mesoblast Limited recently announced it has completed patient recruitment for its pivotal Phase 3 trial of rexlemestrocel-L in chronic low back pain due to degenerative disc disease, a placebo-controlled study following at least 300 patients for 12 months. This milestone moves the program closer to potential FDA filing for rexlemestrocel-L, which holds RMAT designation in a multi-million patient indication closely linked to prescription opioid use. We’ll now examine how reaching full...